Dr. Reddy’s facility struck by another Form 483

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Aramyan)
(Image: Getty/Aramyan)

Related tags: India, Fda, Form 483

Dr. Reddy’s Bachupally manufacturing plant has received a second Form 483 from the US FDA in the past two years.

The Indian company did not release many details​ regarding the US Food and Drug Administration (FDA)’s findings, only noting that the Hyderabad-based manufacturing plant received 11 observations.

The company stated, “We will address [the observations] comprehensively within the stipulated timeline.”

This is the second time that the formulation manufacturing plant has seen FDA regulatory action at the facility, after it was issued a Form 483 in May 2017​. During the previous inspection that resulted in a Form 483, the agency also found 11 observations, which the company told us, at the time, were ‘mostly procedural’.

The Hyderabad site houses three formulation plants, the most recent inspection relates to ‘plant 3’; the space that also holds the company’s global office, as well as three active pharmaceutical ingredient (API) manufacturing facilities and four R&D sites.

Problems at the site also extended to an API plant, which was issued a Form 483 in March 2018​.

Six months ago, the company sold an API plant​ to the generic joint venture, Therapiva. The company noted the decision to sell was to streamline its business to ‘optimise’ global costs.

Shares in Dr. Reddy’s dipped 4% on the news, dropping from ₹2776 ($39.31) on the release of the news to ₹2663 ($37.71), as of the time of reporting.

Related news

Show more

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars